Immunic (HAM:10V) Market Cap: €180.80 Mil (As of Jun. 26, 2026)


HAM:10V Immunic Inc HAM:10V
32 GF Score
Price €7.56
! 3 Warning Signs
View Full Analysis

What is Immunic Market Cap?

Immunic HAM:10V 32 Market Cap is €180.80 Mil as of Jun. 26, 2026. GuruFocus rates HAM:10V with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, Immunic ranks better than 58.07% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Immunic's share price for the quarter that ended in Mar. 2026 was €9.06. Immunic's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 13.62 Mil. Therefore, Immunic's market cap for the quarter that ended in Mar. 2026 was €123.41 Mil.

Immunic's quarterly market cap increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€53.27 Mil) and increased from Dec. 2025 (€53.27 Mil) to Mar. 2026 (€123.41 Mil).

Immunic's annual market cap stayed the same from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€53.27 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Immunic's Enterprise Value for Today is €16.79 Mil.


Immunic  (HAM:10V) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Immunic Market Cap Related Terms


Immunic Market Cap Historical Data

* Premium members only.

The historical data trend for Immunic's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic Market Cap Chart

Immunic Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 53.27

Immunic Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 53.27 123.41

HAM:10V vs KPTI, INDP, UNCY: Market Cap Comparison

For the Biotechnology subindustry, Immunic's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Market Cap distribution charts can be found below:

* The bar in red indicates where Immunic's Market Cap falls into.


HAM:10V
32GF Score
Immunic Inc HAM:10V
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunic Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Immunic's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=€4.425*12.038
=€53.27

Immunic's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=€9.06*13.621
=€123.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of €180.80 Mil mean?
Immunic (HAM:10V) has a Market Cap of €180.80 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Immunic and its competitors. According to the industry distribution chart, Immunic ranks #600 out of 1431 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Immunic's Market Cap too high?
Immunic's current Market Cap is €180.80 Mil. Based on the distribution chart, Immunic ranks #600 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's Market Cap compare to KPTI and INDP?
According to the Biotechnology industry distribution chart, Immunic ranks #600 out of 1431 companies for Market Cap. This puts Immunic in the upper half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Immunic and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunic's current Market Cap is €180.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (HAM:10V) has a current Market Cap of €180.80 Mil. The current Market Cap is €180.80 Mil. Immunic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Immunic (HAM:10V), the current Market Cap is €180.80 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunic Business Description

Other Exchanges IMUX:USA10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for HAM:10V

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.56
Price